# MiR-200c restoration inhibits FOXP3 and metastatic spread in breast cancer: evidence from in vitro and in vivo models

**Authors:** Nashwa El-Khazragy, Ahmed Alsolami, Ahmed M. Aref, Marwa N. M. Hassan, Mohamed S. Othman

PMC · DOI: 10.1186/s12885-026-15574-6 · BMC Cancer · 2026-02-14

## TL;DR

Restoring miR-200c in breast cancer cells reduces tumor spread by inhibiting FOXP3, offering a potential new treatment for advanced breast cancer.

## Contribution

This study demonstrates that miR-200c restoration suppresses metastasis by targeting FOXP3 in breast cancer.

## Key findings

- MiR-200c overexpression reduced proliferation and invasion while increasing apoptosis in metastatic breast cancer cells.
- MiR-200c mimic treatment reduced tumor burden and metastasis in a mouse model.
- A strong inverse correlation between miR-200c and FOXP3 was observed in treated cells and tissues.

## Abstract

Metastatic breast cancer remains a leading cause of cancer-related mortality in women, often driven by molecular pathways that promote invasion and immune evasion. MicroRNA-200c (miR-200c) is a known tumor suppressor that inhibits epithelial-mesenchymal transition (EMT), while FOXP3, a transcription factor typically associated with regulatory T cells, is aberrantly expressed in breast cancer cells and may contribute to tumor progression. This study investigates whether targeting the miR-200c/FOXP3 axis can suppress metastasis in breast cancer.

Metastatic (MDA-MB-361, MDA-MB-468) and non-metastatic (MCF-7) breast cancer cell lines were transfected with miR-200c mimic or inhibitor. Cell proliferation, apoptosis, and invasion were assessed using MTT, Annexin V/PI staining, and transwell assays. FOXP3 mRNA and protein levels were quantified using qRT-PCR and immunohistochemistry. A metastatic mouse model was established via intracardiac injection of tumor cells, followed by treatment with miR-200c mimic, inhibitor, or Cisplatin.

MiR-200c overexpression significantly suppressed proliferation and invasion and enhanced apoptosis in metastatic cells. FOXP3 mRNA and protein expression were downregulated in mimic-treated cells and tissues, while miR-200c inhibition led to increased FOXP3 expression. In vivo, miR-200c mimic treatment reduced tumor burden and metastatic infiltration in the brain and lungs. A strong inverse correlation between miR-200c and FOXP3 was observed (r = − 0.82, p < 0.01).

MiR-200c restoration inhibits FOXP3 and suppresses metastatic progression in breast cancer. Targeting the miR-200c/FOXP3 axis presents a novel and promising therapeutic approach for advanced breast cancer.

## Linked entities

- **Genes:** MIR200C (microRNA 200c) [NCBI Gene 406985], FOXP3 (forkhead box P3) [NCBI Gene 50943]
- **Proteins:** FOXP3 (forkhead box P3)
- **Chemicals:** Cisplatin (PubChem CID 5460033)
- **Diseases:** breast cancer (MONDO:0004989)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Mir141 (microRNA 141) [NCBI Gene 387159] {aka Mirn141, mir-141, mmu-mir-141}, Anxa5 (annexin A5) [NCBI Gene 11747] {aka Anx5, CPB-I}, FSD1 (fibronectin type III and SPRY domain containing 1) [NCBI Gene 79187] {aka GLFND, MIR1}, ANXA5 (annexin A5) [NCBI Gene 308] {aka ANX5, CPB-I, ENX2, HEL-S-7, PP4, RPRGL3}, Foxp3 (forkhead box P3) [NCBI Gene 20371] {aka JM2, scurfin, sf}, POTEF (POTE ankyrin domain family member F) [NCBI Gene 728378] {aka A26C1B, POTE2alpha, POTEACTIN}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, FOXP3 (forkhead box P3) [NCBI Gene 50943] {aka AIID, DIETER, IPEX, JM2, PIDX, XPID}, PGR (progesterone receptor) [NCBI Gene 5241] {aka NR3C3, PR}, Mir200c (microRNA 200c) [NCBI Gene 723944] {aka Mirn200c, mir-200c}, MIR200C (microRNA 200c) [NCBI Gene 406985] {aka MIRN200C, mir-200c}, MIR141 (microRNA 141) [NCBI Gene 406933] {aka MIRN141, mir-141}, MIR34A (microRNA 34a) [NCBI Gene 407040] {aka MIRN34A, miRNA34A, mir-34, mir-34a}, IARS1 (isoleucyl-tRNA synthetase 1) [NCBI Gene 3376] {aka GRIDHH, IARS, ILERS, ILRS, IRS, PRO0785}, EREG (epiregulin) [NCBI Gene 2069] {aka EPR, ER, Ep}, TWSG1 (twisted gastrulation BMP signaling modulator 1) [NCBI Gene 57045] {aka TSG}
- **Diseases:** IACUC (MESH:D000820), Necrotic (MESH:D009336), colorectal, lung, ovarian, prostate, and bladder (MESH:D010049), IMDM (MESH:C564098), pleural effusion (MESH:D010996), ductal carcinoma (MESH:D044584), BC (MESH:D001943), lung adenocarcinoma (MESH:D000077192), TNBC (MESH:D064726), cytotoxic (MESH:D064420), weight loss (MESH:D015431), Metastatic (MESH:D000092182), epithelial malignancies (MESH:D002277), adenocarcinoma (MESH:D000230), SDS-HCL (MESH:C562576), cancer (MESH:D009369), tumorigenic (MESH:D002471), Lung metastases (MESH:D009362)
- **Chemicals:** formalin (MESH:D005557), 3,3'-diaminobenzidine (MESH:D015100), eosin (MESH:D004801), Hydrochloric Acid (MESH:D006851), Sodium Dodecyl Sulfate (MESH:D012967), isoflurane (MESH:D007530), penicillin G sodium (MESH:D010400), water (MESH:D014867), guanidine-thiocyanate (MESH:C054436), CO2 (MESH:D002245), trastuzumab (MESH:D000068878), phosphatidylserine (MESH:D010718), streptomycin (MESH:D013307), amphotericin B (MESH:D000666), MTT (MESH:C070243), nitrogen (MESH:D009584), EDTA (MESH:D004492), HI (MESH:D006639), Phosphate (MESH:D010710), PI (MESH:D010716), Hematoxylin (MESH:D006416), penicillin (MESH:D010406), Paraffin (MESH:D010232), Invivofectamine 3.0 (-), Cisplatin (MESH:D002945), PI (MESH:D011419), saline (MESH:D012965), H&amp;E (MESH:D006371), methanol (MESH:D000432), crystal violet (MESH:D005840)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** rs701848
- **Cell lines:** HNO97 — Homo sapiens (Human), Tongue squamous cell carcinoma, Cancer cell line (CVCL_D227), MCF-7 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0031), M6494 — Homo sapiens (Human), Amyotrophic lateral sclerosis, Transformed cell line (CVCL_VA84), MDA-MB-468 — Homo sapiens (Human), Breast adenocarcinoma, Cancer cell line (CVCL_0419), ATCC- HTB-132 — Mus musculus (Mouse), Hybridoma (CVCL_A8FQ), 310 +- 12.6 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_5398), MDA-MB-361 — Homo sapiens (Human), Breast adenocarcinoma, Cancer cell line (CVCL_0620)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12930562/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12930562/full.md

## References

4 references — full list in the complete paper: https://tomesphere.com/paper/PMC12930562/full.md

---
Source: https://tomesphere.com/paper/PMC12930562